Background: Respiratory alemtuzumab-related adverse events are clinically heterogeneous and include respiratory infections, infusion-related dyspnea, hypoxia and secondary autoimmune disorders. Case report: Here we report three cases of drug-induced lung disease following treatment with alemtuzumab in multiple sclerosis patients. First case was diagnosed as a non-specified intestitial pneumonitis associated with organizing pneumonia with subacute onset, second case was an acute respiratory distress syndrome with onset during second cycle, third case was a diffuse acute alveolar hemorrhage during first cycle infusion. All patients developed acute respiratory failure, reversible after steroid therapy. Conclusions: Clinicians should be aware to early recognize acute and subacute respiratory adverse events for a promptly management. In these patients re-treatment is challenging.
Bianco, A., Mari, P., Larici, A. R., Lucchini, M., Nociti, V., Losavio, F. A., De Fino, C., Cicchetti, G., Coraci, D., Richeldi, L., Mirabella, M., Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients, <<MULTIPLE SCLEROSIS AND RELATED DISORDERS>>, 2020; 37 (37): 101450-101453. [doi:10.1016/j.msard.2019.101450] [http://hdl.handle.net/10807/151231]
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients
Bianco, Assunta
;Mari, Pier-Valerio;Larici, Anna Rita;Lucchini, Matteo;Nociti, Viviana;Losavio, Francesco Antonio;De Fino, Chiara;Cicchetti, Giuseppe;Coraci, Daniele;Richeldi, Luca;Mirabella, Massimiliano
2020
Abstract
Background: Respiratory alemtuzumab-related adverse events are clinically heterogeneous and include respiratory infections, infusion-related dyspnea, hypoxia and secondary autoimmune disorders. Case report: Here we report three cases of drug-induced lung disease following treatment with alemtuzumab in multiple sclerosis patients. First case was diagnosed as a non-specified intestitial pneumonitis associated with organizing pneumonia with subacute onset, second case was an acute respiratory distress syndrome with onset during second cycle, third case was a diffuse acute alveolar hemorrhage during first cycle infusion. All patients developed acute respiratory failure, reversible after steroid therapy. Conclusions: Clinicians should be aware to early recognize acute and subacute respiratory adverse events for a promptly management. In these patients re-treatment is challenging.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.